

### Adherence 2017

JUNE 4-6, 2017 • MIAMI

Jointly sponsored by







# Brazil, Test and Treat and 90-90-90: using continua and 90-90-90 to monitor progress towards national and local targets


Ana Roberta Pati Pascom, PhD, MSc STI, AIDS and Viral Hepatits Department Ministry of Health of Brazil

#### 5 things you should know about Brazil and its HIV epidemic


#ADHERENCE201


- 1. 200M population, 27 States, 5,561 municipalities
- 1988: right to health care was established in the Federal Constitution (Health System -SUS)
- 3. Free and universal access to since 1988
- 4. December 2013: first developing country and third country in the world to implement treatment for all (free of charge)
- 5. In 2016, ~70K people initiated ART in Brazil and, by December 2016, 500K PLWH were on ART






ART was guaranteed by SUS





#### 90-90-90 Goals in Brazil




#### 90-90-90 Goals in Brazil


Monthly reports on basic indicators, such as:

- Late diagnosis
- CD4 before ART initiation
- PLWH on ART
- Viral Suppression





#ADHERENCE201



90-90-90 Goals in Brazil:


Challenges

 Estimate the number of PLWH, especially for states and cities


 Adoption of standardized method to estimate the steps of the cascade to allow comparison between cities (based on Brazilian information systems)

Lack of information related to KP


Delay in the implementation of HIV notification (only 2014)



#ADHERENCE20



## Brazilian Information Systems: #ADHERENCE2017 an opportunity to monitor 90-90-90 targets



## 90-90-90 Goals in Brazil: the way forward



- Include FTC in the clinical monitoring report (it will be launched by July/2017)
- Enhance information on key variables, including exposure category in the Brazilian systems (lab and ARV dispensation)
  - Assessing the feasibility
  - Use of imputation
  - KP cascades
- Diminish the time gap between information and action
- Development of PMTCT cascades and vertical transmission rate based on the lab and ARV dispensation system





#### **Acknowledgments**

- Dra Adele Benzaken
- M&E Team

#### Thanks!

ana.roberta@aids.gov.br